Ignyta, Inc. (RXDX) [Rocket]

Date Filed	Type	Description
01/23/2018	GN	Recent Analysis Shows Ignyta, Twenty-First Century Fox, Helios and Matheson Analytics, XO Group, Tyler Technologies, and UMH Properties Market Influences — Renewed Outlook, Key Drivers of Growth
11/22/2017	BW	Ignyta to Present at the 29th Annual Piper Jaffray Healthcare Conference
11/20/2017	GN	New Research: Key Drivers of Growth for Scana, Goldman Sachs Group, FMC, DineEquity, Ignyta, and Barnes & Noble — Factors of Influence, Major Initiatives and Sustained Production
11/09/2017	BW	Ignyta to Present at the Jefferies 2017 London Healthcare Conference
11/07/2017	BW	Ignyta Announces Third Quarter 2017 Company Highlights and Financial Results
10/19/2017	BW	Ignyta Announces Pricing of Public Offering of Common Stock
10/17/2017	BW	Interim Analysis of Ignyta's Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
09/27/2017	BW	Ignyta Announces Updated Data on Entrectinib in ROS1 NSCLC to Be Presented at the IASLC 18th World Conference on Lung Cancer
09/20/2017	BW	Ignyta to Present at Cantor Fitzgerald 2017 Global Healthcare Conference
09/11/2017	BW	Ignyta Provides Update on Entrectinib and RXDX-105 at the ESMO 2017 Congress
09/07/2017	BW	Ignyta Announces Presentation of New Phase 1B Clinical Data on RXDX-105 in RET Fusion-Positive NSCLC at ESMO 2017 Congress
09/06/2017	BW	Ignyta Provides Regulatory Update on Entrectinib ROS1 Lung Cancer Development Program
08/08/2017	BW	Ignyta Announces Second Quarter 2017 Company Highlights and Financial Results
05/02/2017	BW	Ignyta Announces Proposed Public Offering of Common Stock